Theravance Biopharma Inc (TBPH) FinancialsTBPHTheravance Biopharma Inc

Evaluating the bottom line, Theravance Biopharma, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 8.89%, while the net margin is -28.45%. These profitability ratios, combined with a Return on Equity (ROE) of 20.91%, provide a clear picture of how effectively TBPH converts its operational activities into shareholder value.

In the context of the broader market, TBPH competes directly with industry leaders such as ACRS and OLMA. With a market capitalization of $885.21M, it holds a significant position in the sector. When comparing efficiency, TBPH's gross margin of 100.00% stands against ACRS's 10.80% and OLMA's N/A. Such benchmarking helps identify whether Theravance Biopharma, Inc. is trading at a premium or discount relative to its financial performance.

Theravance Biopharma reported a significant turnaround in net income with $61,024,000 in Q4 2025, but has seen negative net income in recent quarters, including -$5,893,000 in Q2 2026. The gross margin remains strong at 100% across recent quarters, indicating effective cost management.